Relevium Technologies Appoints Mark Billings as Chief Financial Officer
08 November 2019 - 1:11AM
Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB:“RLLVF” and
Frankfurt: “6BX”) (the “Company” or “Relevium”), is pleased to
announce the appointment of Mark Billings, CFA as Chief Financial
Officer for both Relevium and Biocannabix Health Corporation
effective immediately. Mr. Billings replaces Faycal Salek who has
resigned to pursue other opportunities.
Mr. Billings is an experienced executive
Chartered Financial Analyst and a graduate of the Harvard School of
Business. Mr. Billings has founded and managed companies in the
junior resource sector, where he acted as CEO, CFO and board
member. Mr. Billings serves on the board of several publicly traded
resource companies in Canada and abroad. In addition to his
executive career, Mr. Billings has been an investment banker,
having raised hundreds of millions of dollars for small-cap
companies, including several junior mining companies.
Aurelio Useche, CEO
of Relevium stated: “Mr. Billings is a veteran in
the public markets and brings to our company extensive experience
in capital markets, M&A transactions and overall financial
acumen, all of which are necessary for the next stage of the
development of our business. We look forward to his active
participation in the strategic planning process, development and
execution of the company’s objectives”
Mr. Useche continued: “On behalf of the entire
board and management team, we would like to thank Mr. Faycal Salek
for his valuable contributions and wish him success in his new
endeavors.”
About Relevium
TechnologiesRelevium is a publicly traded company that
operates in the health and wellness industry, including legal
cannabis, with a primary focus on online distribution. The
principal business of the Company is the identification,
evaluation, acquisition and operation of brands and businesses in
the health and wellness markets and medical cannabis. The Company
pursues its business strategy through an acquisition and
partnership model in a holistic approach to encompass a wide range
of health and wellness consumer products. Relevium operates through
two wholly owned subsidiaries:
BGX E-Health LLC (BGX), based in Orlando,
Florida, markets dietary supplements, nutraceuticals, sports
nutrition and cosmeceuticals primarily through its Bioganix® brand
portfolio in the US and Europe. Relevium’s premium brands are sold
at some of the world’s largest retailers including Walmart.com and
Amazon.com.
Biocannabix Health Corporation (BCX), based in
Montreal, Quebec, is a biopharma nutraceutical company focused on
delivering pediatric endo-medicinal nutraceuticals for cannabinoid
therapy. The Company has an international ecosystem and footprint
that ensures vertical integration from phyto-genetics through
clinical validation and eventual commercialization of its
products.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in policies
of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this release.
Cautionary Note Regarding
Forward-Looking Statements
This release includes certain statements and
information that may constitute forward-looking information within
the meaning of applicable Canadian and United States securities
laws. All statements in this news release, other than statements of
historical facts, including statements regarding future estimates,
plans, objectives, assumptions or expectations of future
performance, are forward-looking statements and contain
forward-looking information. Generally, forward- looking statements
and information can be identified using forward-looking terminology
such as "intends" or "anticipates", or variations of such words and
phrases or statements that certain actions, events or results
"may", "could", "should", or "would" occur. Forward-looking
statements are based on certain material assumptions and analysis
made by the Company and the opinions and estimates of management as
of the date of this press release. These forward-looking statements
are subject to known and unknown risks, uncertainties and other
factors that may cause the actual results, level of activity,
performance or achievements of the Company to be materially
different from those expressed or implied by such forward-looking
statements or forward-looking information.
Although management of the Company has attempted
to identify important factors that could cause actual results to
differ materially from those contained in forward-looking
statements or forward-looking information, there may be other
factors that cause results not to be as anticipated, estimated or
intended. There can be no assurance that such statements will prove
to be accurate, as actual results and future events could differ
materially from those anticipated in such statements. Accordingly,
readers should not place undue reliance on forward- looking
statements and forward-looking information. Readers are cautioned
that reliance on such information may not be appropriate for other
purposes. The Company does not undertake to update any
forward-looking statement, forward-looking information or financial
outlook that are incorporated by reference herein, except in
accordance with applicable securities laws. We seek to rely on the
applicable safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES
INC.Aurelio UsechePresident and CEO
For more information about this press
release:
Tel: +1.888.528.8687
RELEVIUM TECHNOLOGIES INCEmail:
investors@releviumcorp.comWebsite: www.releviumtechnologies.com
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jun 2024 to Jul 2024
Relevium Technologies (TSXV:RLV)
Historical Stock Chart
From Jul 2023 to Jul 2024